This review introduces a new strategy
Animal model for diabetic nephropathy Non-enzymatic glycation has been implicated in the pathogenesis of diabetic nephropathy. There are multiple pathways for the formation of AGEs, including N -(carboxymethyl) lysine (CML), N e -(carboxyethyl) lysine (CEL) and pentosidine, from glucose, products of antioxidation of glucose, Schiff bases and Amadori products. The presence of AGEs is closely related to hyperglycemia and their pathobiochemistry could explain diabetic nephropathy. Specific AGEs, such as CML, are major products of glycoxidation reactions. In therapeutic interventions for reducing AGEs, many compounds have been reported as AGE inhibitors, such as aminoguanidine, phenacyl thiazolium bromide, 2 -isopropylidenehydrazono-4 -oxo-thiazolidine-5 -yl-acetanilide (OPB-9195), 2, 3-diaminophenazine, vitamin C, vitamin E, angiotensin II receptor inhibitors and pyridoxamine7 Immunopathological studies were performed to determine whether glomerular injuries in ddY mice are influenced by treatment with a newly developed liposome loaded with prednisolone phosphate ( PSL-liposome) 14) . The synthesized novel cationic lipid 3, 6 -dipentadeciroxy-1 -amizino-benzene (TRX-20) was employed to obtain selective affinity to the anionic cell surface and ECM in glomerular mesangial lesions. ddY mice were treated intravenously with 1. 0 mg/kg of PSL-liposome once a week from 45 weeks to 61 weeks of age. ddY mice were also intravenously treated with 1. 0 mg/kg of ordinary PSL once a week. In immunofluorescence, mean intensity of IgA and C3 depositions in glomeruli of PSL-liposometreated ddY mice were markedly decreased when compared with those of ordinary PSL-treated and untreated control ddY mice. Glomerular mesangial expansion in PSL-liposome-treated ddY mice was milder than that in ordinary PSL-treated ddY mice or untreated control ddY mice. It appears that treatment with PSL-liposome is effective in improving glomerular IgA and C3 depositions and glomerular expansion in IgA nephropathy of ddY mice.
b. Immunosuppressants
Mizoribine, an immunosuppressant, was developed in Japan and shown to prevent the proliferation of lymphocytes in vitro and to possess immunosuppressive action in vivo. Since mizoribine also has a suppressive effect on antibody formation via direct inhibition of B-cell function, it has beneficial effects in patients with chronic glomerulonephritides, lupus nephritis, nephrotic syndrome and renal transplanta- Immunopathological studies were performed to determine whether glomerular injuries in ddY mice are influenced by treatment with a monoclonal antibody (mAb) to murine CD4 molecules16). The ddY mice were initially treated with intravenous injections, followed by weekly intraperitoneal injections of mAb CD4. Flow cytometry showed that there was a marked decrease in the number of CD4 T cells. In immunofluorescence, the mean intensity of IgA deposits in the glomerular mesangial areas and capillary walls of treated ddY mice was significantly lower than that in saline-treated control ddY mice of comparable age. Glomerular mesangial expansion in the treated ddY mice was milder than that in the same control ddY mice. However, no significant differences in the levels of serum IgA, urinary protein excretion, and average number of intraglomerular cells were observed between the treated and control ddY mice. It appears that although CD4 T cells control the amount of IgA deposits in glomeruli, other factors may be involved in the evolution of IgA nephropthy in ddY mice. It is not known whether the increase observed in the number of intraglomerular cells in both treated and control ddY mice is due to resident glomerular cells or mononuclear cells infiltrating the glomeruli. Our studies showed that increased glomerular cells in ddY mice are positive for markers of Thy-1. 2 (total T cells), CD8 (killer/suppressor T-cells) and CD 11 (mac-1, macrophages/monocytes), suggesting that the majority of these cells are likely to be infiltrating cells and glomerular mesangial cells. Since several cytokines or growth factors such as IL-1, IL-6, TNF a and platelet-derived growth factor (PDGF) have been shown to be involved in mesangial cell proliferation, it was suggested that, in addition to the effect of CD4 + T cells that may modulate the amount of glomerular IgA deposits, these factors may be involved in the progressive mechanism of IgA nephropathy.
d. Bone marrow transplantation (BMT)
A previous report demonstrated that in a patient with IgA nephropathy and chronic myeloblastic leukemia, bone marrow transplantation ( BMT) resulted not only in remission of leukemia but also in remission of IgA nephropathy1n. Imasawa et al.18) also reported that BMT from normal mice attenuated glomerular lesions in a murine model of IgA nephropathy, HIGA (high serum IgA ddY) mice, while the glomerular lesion associated with IgA deposition was reconstituted in normal recipient mice after BMT from HIGA mice. These findings indicated that IgA nephropathy may involve disorders of stem cells. The ddY mouse is known as a spontaneous murine IgA nephropathy model, but the incidence of IgA nephropathy is highly variable. Suzuki et al., my colleagues, recently observed that ddY mice could be classified into three groups, the early onset (20 weeks), late onset (40 weeks), and quiescent groups by serial renal biopsies that confirm glomerular lesions and IgA deposition19). A genome-wide association study of the early onset and the quiescent mice revealed that the susceptibility to murine IgA nephropathy is partly regulated by specific loci syntenic to the IgANI gene known as a candidate gene of human familial IgA nephropathy19)20) . These results indicated the suitability of the grouped ddY mouse model for examining the pathogenesis of IgA nephropathy. Although the potential of bone marrow derived cells (BMC) to differentiate to glomerular cells has been discussed, the role of BMC in the kidney is still obscure. The mechanism of glomerular immune-complex deposition and the role of BMC in the kidneys were examined using ddY mice. In 2007, Suzuki et al. also reported that BMC are responsible for the induction of IgA nephropathy21). BMT from the early onset ddY mice resulted in mesangioproliferative glomerular injury with mesangial IgA and IgG depositions in the recipient-quiescent ddY mice. In contrast, BMT from quiescent ddY mice resulted in reduction of not only glomerular injury but also mesangial IgA and IgG depositions in the recipient-early onset ddY mice ( Figures-2 and 3) . BMT from the early onset ddY mice caused progression of urinary albumin levels in the recipient-quiescent ddY mice, and also caused a marked increase of urinary albumin levels in the recipient-early onset ddY mice. It appears that BMC, presumed to be IgA producing cells, may initiate IgA nephropathy.
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